VIDO-InterVac

Vaccine and Infectious Disease Organization -
International Vaccine Centre

Hepatitis C viral pathogenesis

Project Leader: Qiang Liu

Hepatitis C virus (HCV) is an important infectious disease affecting between 300,000-500,000 Canadians and 130-150 million people globally. Although there is no vaccine for HCV, the disease is controlled by direct-acting antivirals (DAAs) that target viral proteins. Unfortunately due to the error-prone nature of HCV replication, the development of viral resistance is an issue. DAAs are also costly and have numerous associated side-effects.Due to these factors, the identification on novel druggable targets in the host is a top priority.

Our research is focused on identifying druggable targets through improved understanding of the molecular mechanisms regulating HCV replication and pathogenesis. This includes determining how HCV translation is regulated by viral and cellular factors. We will also target understanding the role co-infections play in HCV pathogenesis.

Objectives:

  • Identify novel druggable targets
  • Study mechanisms regulating HVC replication
  • Determine how HCV RNA translation is regulated by viral and cellular factors
  • Understand the pathogenesis of hepatitis B virus and hepatitis C virus co-infections